Davis Capital Management
CTKB icon

Davis Capital Management’s Cytek Biosciences CTKB Stock Holding History

Davis Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$66 Sell
11
-1
-8% -$5 ﹤0.01% 1097
2026
Q2 		$53 Buy
+12
New +$51 ﹤0.01% 1200

Other funds holding CTKB

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
Everhart Financial Group
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
NorthCrest Asset Manangement
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
PWMG
Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
SJS Investment Consulting
SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

Davis Capital Management's CTKB Position: Q3 2026 in Review

Davis Capital Management reduced its Cytek Biosciences (CTKB) stake by 8.3% in Q3 2026, selling an estimated $5 and leaving 11 shares worth $66. The position accounts for ﹤0.01% of the portfolio, ranked #1097.

Davis Capital Management first reported a position in CTKB in Q2 2026 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • Davis Capital Management held 11 shares of Cytek Biosciences worth $66 as of Q3 2026.
  • Davis Capital Management sold 1 Cytek Biosciences share in Q3 2026, an estimated $5.
  • Cytek Biosciences made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #1097 holding.
  • Davis Capital Management first reported a position in Cytek Biosciences in Q2 2026 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.